scholarly journals Factors Associated With The Prevalence And Severity of Nausea While Undergoing Radiation Among Women Diagnosed With Early-Stage Breast Cancer

2021 ◽  
Author(s):  
Caroline Harpel ◽  
Susan M. Sereika ◽  
Karen Alsbrook ◽  
Susan Grayson ◽  
Susan Wesmiller
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Binary Logistic Regression ◽  
Breast Cancer Risk Factor ◽  
Early Stage Breast Cancer ◽  
Breast Radiotherapy ◽  
Severity Rating ◽  
Younger Age ◽  
History Of ◽  
Reported Data

Abstract Purpose. The purpose of this study was to estimate radiation-induced nausea (RIN) prevalence and severity among 183 women with early-stage breast cancer and to identify its predictors. Methods. Among participants who underwent radiotherapy, a case-control design compared those who experienced RIN to those who did not. Nausea was measured weekly and operationalized on an 11-point scale with ‘0’ representing “no nausea” and ’10’ representing the “worst nausea ever experienced.” Participants self-reported these symptoms while undergoing radiotherapy. Predictor variables were identified using multivariable binary logistic regression for RIN prevalence and multiple linear regression for RIN severity. Results. Over forty percent (n=75) of participants undergoing radiotherapy experienced RIN, with a mean nausea severity rating of 3.27/10. Significant predictors of RIN prevalence were higher pain levels (p<0.0001), history of motion sickness (p=0.024), and younger age (p=0.032). Higher pain levels (p<0.0001), younger age (p=0.038) and history of postoperative nausea (p=0.042) were significant predictors of increased RIN severity. Conclusions. The RIN prevalence of 41.0 percent among study participants was higher than previously reported for patients undergoing breast radiotherapy. This could be due to the collection of weekly self-reported data that quantified RIN severity. Younger age, history of nausea, and higher average pain levels should be identified as potential RIN risk factors among patients with early-stage breast cancer. Risk factor identification at the onset of radiotherapy would allow for increased prophylactic mitigation of RIN.

scholarly journals Medical comorbidities predict mortality in women with a history of early stage breast cancer

2010 ◽  
Vol 122 (3) ◽  
pp. 859-865 ◽  
Author(s):  
Ruth E. Patterson ◽  
Shirley W. Flatt ◽  
Nazmus Saquib ◽  
Cheryl L. Rock ◽  
Bette J. Caan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Medical Comorbidities ◽  
History Of

scholarly journals Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Linwei Wang ◽  
Min Sun ◽  
Shuailong Yang ◽  
Yuanyuan Chen ◽  
Tian Li
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Therapeutic Option ◽  
Meta Analysis ◽  
Intraoperative Radiotherapy ◽  
Recurrence Risk ◽  
Early Stage Breast Cancer ◽  
Breast Radiotherapy ◽  
Whole Breast Radiotherapy

ObjectiveIntraoperative radiotherapy (IORT) in early-stage breast cancer has been studied over the years. However, it has not been demonstrated whether IORT is more suitable as a therapeutic option for early-stage breast cancer than whole breast radiotherapy (WBRT). Therefore, we performed a meta-analysis to compare the efficacy and safety of IORT to those of WBRT as therapeutic options for early-stage breast cancer patients receiving breast-conserving surgery (INPLASY2020120008).MethodsPubMed, Embase, and Cochrane Library databases were searched from inception to October 2021. Computerized and manual searches were adopted to identify eligible randomized control trials from online databases. Risk ratio (RR) and 95% confidence intervals (CI) were calculated by random-effect models to assess the relative risk. Potential publication bias was quantified by Begg’s and Egger’s tests.ResultsBased on our inclusion criteria, 10 randomized control trials involving 5,698 patients were included in this meta-analysis. This meta-analysis showed that the IORT group was associated with a higher local recurrence risk (RR = 2.111, 95% CI, 1.130–3.943, p = 0.0191), especially in the long-term follow-up subgroup or published after 2020 subgroup or Caucasian subgroup (RR = 2.404, 95% CI, 1.183–4.885, p = 0.0154). Subgroup analysis showed that the IORT group had a higher recurrence risk than the WBRT group in the polycentric randomized controlled trial subgroup (RR = 1.213, 95% CI, 1.030–1.428, p = 0.0204). Pooled analysis showed that there was no statistically significant difference in overall survival, recurrence-free survival, distant metastasis-free survival, and cancer-specific survival between IORT and WBRT groups. Additionally, the risk of skin toxicity was reduced, but the incidences of fat toxicity, edema, and scar calcification were significantly increased in the patients who underwent IORT in comparison to those who underwent WBRT.ConclusionThis meta-analysis revealed that IORT was not a better alternative to WBRT. More large-scale and well-designed clinical trials with longer follow-up periods are encouraged to further investigate the value of IORT.Systematic Review Registrationhttps://inplasy.com/inplasy-2020-12-0008/.

Prevalence and predictors of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study.

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 185-185
Author(s):  
Allison W. Kurian ◽  
Christopher Ryan Friese ◽  
Irina Bondarenko ◽  
Reshma Jagsi ◽  
Steven J. Katz
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Early Stage ◽  
Multivariable Analysis ◽  
Recurrence Score ◽  
Early Stage Breast Cancer ◽  
Clinical Indication ◽  
P Value ◽  
Medical Oncologists ◽  
Younger Age

185 Background: A second medical oncology opinion (SMO) may facilitate chemotherapy decision-making. However, little is known about the interplay between SMOs, treatment decision-making and chemotherapy use. Methods: We surveyed women newly diagnosed with early-stage invasive breast cancer and treated in 2013-2014 (response rate 70%), accrued approximately 3 months after surgery through 2 population-based SEER registries (Georgia and Los Angeles), about their experiences with medical oncologists, decision-making, and chemotherapy use. We evaluated demographic, clinical and decisional factors associated with SMO using logistic regression, and evaluated the association between SMO and chemotherapy, adjusting for clinical indication for chemotherapy, results of the 21-gene recurrence score assay, and estimated propensity for SMO given patient and tumor-specific characteristics. Results: Among 1182 insured patients who consulted any medical oncologist, 8.7% had SMO and 2.4% received chemotherapy from the SMO provider. On multivariable analysis, predictors of SMO use were younger age (odds ratio, OR 0.97 per year, 95% confidence interval, CI 0.94-0.99), education (college vs. high school graduate, OR 1.88, CI 1.06-3.33), an intermediate 21-gene recurrence score (OR 2.21, CI 1.18-4.16) and a variant of uncertain significance on BRCA1/2 gene testing (OR 5.61, CI 1.22-25.72). Satisfaction with chemotherapy decision-making was high and did not differ between patients who did vs. did not receive SMO (85.3% quite or totally satisfied vs. 86%, p-value 0.85). On multivariable analysis, chemotherapy use did not differ between SMO recipients vs. non-recipients (p-value 0.25). Conclusions: SMO use was low among early-stage breast cancer patients, and was not followed by more or less receipt of chemotherapy. High decision satisfaction regardless of SMO use suggests little unmet demand. Along with younger age and more education, the factor that predicted SMO use was uncertain results of genomic testing. Studies of precision medicine should track patients’ demand for SMO, which may rise with the dissemination of increasingly complex genomic tests. Funding: P01-CA-163233

Impact of age on racial disparity in early stage breast cancer in the United States.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e19058-e19058
Author(s):  
Shruti Bhandari ◽  
Rohit Kumar ◽  
Phuong Ngo ◽  
Sarah Mudra ◽  
Drew Carl Drennan Murray ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Racial Disparities ◽  
Racial Disparity ◽  
Early Stage ◽  
Age Groups ◽  
The United States ◽  
Early Stage Breast Cancer ◽  
Age Group ◽  
Risk Of Mortality ◽  
Younger Age

e19058 Background: Racial disparities persists in women with early stage breast cancer and is most pronounced in Black (B) compared to White (W) women even when controlled for stage and biological subtype. Little is known about the impact of age on racial disparities. Our study evaluates the magnitude of a racial disparity in mortality across age strata in a real-world population. Methods: We identified stage I-III female breast cancer patients between 2010 – 2015 from the National Cancer Database. Hazard ratios (HR) and 95% Confidence Intervals (CI) for all-cause mortality were estimated using multivariable Cox Proportional Hazards regression, adjusted for clinical and demographic factors. The mortality risk for B and Other (O) race was compared to W across four age groups. To determine the significance in excess risk of mortality, the magnitude of disparity of each age group was compared to the > 60y age group. Results: A total of 679,327 patients were included. W comprised the largest percentage across all age groups. However, the percentage of W increased with age, while the percentage of B decreased with age (p < 0.001). The risk of mortality was significantly higher for B relative to W across all age groups ≤60y. When compared to > 60y, the magnitude of effect of age on risk of dying was significantly different (p < 0.0001) (Table). Conversely, the risk of mortality was significantly reduced for O race compared to W, with similar magnitude of effect across all ages. Conclusions: Even after adjusting for known risk factors of racial disparity such as insurance, biologic subtype and stage, the B to W racial disparity in mortality decreased with age (most pronounced in younger age) and appeared to diminish among women > 60 years of age. In contrast, the risk of dying in O race remained constant. Reasons are unclear and may be due to unmeasured socioecomomic or biologic factors that cannot be controlled for in this dataset. Regardless, identifying factors associated with worsened outcomes in younger age groups in B women should be the direction of future studies. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document